Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgia. (20th November 2015)

• Record Type: Journal Article
• Authors: Fais, Antonella; Cacace, Enrico; Atzori, Luigi; Era, Benedetta; Ruggiero, Valeria
• Is Part Of: International journal of rheumatic diseases. Volume 20:Number 5(2017)
• Page Start: 550
• Page End: 554
• Publication Date: 2015-11-20
• Subjects: fibromyalgia -- functional status -- lysophosphocholines -- PAF‐AH -- quality of life -- sPLA 2 -- γ‐CEHC; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.12787
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Objective: Recent studies have suggested a possible role of high levels of plasma lysophosphocholines (lysoPCs) in fibromyalgia syndrome (FMS). The aim of this study was to evaluate the content of plasma phospholipases (e.g., Platelet Activating Factor Acetyl Hydrolase [PAF‐AH], secretory Phospholipase A2 [sPLA2 ], Total Antioxidant Capacity [TAOC] and 2, 7, 8‐trimethyl‐2‐(2‐carboxyethyl)‐6‐hydroxy chroman [γ‐CEHC]) in FMS patients and their association with clinical status and quality of life. Methods: Thirty‐six females meeting the 2011 American College of Rheumatology criteria for the classification of FMS and thirty‐four healthy females were enrolled for the study. Plasma enzyme levels were quantified using commercial enzyme‐linked‐immunosorbent‐assay (ELISA). In order to assess the disease severity and the functional status of patients, the Fibromyalgia Impact Questionnarie (FIQ) was used. Results: Higher levels of sPLA2 and lower PAF‐AH and γ‐CEHC were observed in the plasma of FMS patients compared to the controls. A decrease in PAF‐AH and TAOC levels were found in severe FMS (S‐FMS) compared to mild/slight (MS‐FMS) forms. Conclusion: The results of the study indicate a possible involvement of phospholipases and γ‐CEHC in fibromyalgia syndrome.